Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)

Micah Hamilton; Grace Inserra; Cate Ledoux; Nicholas Streicher

doi:10.1212/wnl.0000000000217595

June 9, 2026Neurology

Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the relationship between serum neurofilament light chain levels and MRI markers of multiple sclerosis progression and relapse.
Evaluated commercially obtained serum neurofilament light chain levels.
Analyzed the association with MRI findings related to multiple sclerosis.
Determined correlations between NfL levels and clinical markers of disease activity.
Higher serum NfL levels correlated with increased MRI-based markers of MS progression.
NfL levels predicted relapse activity with significant correlation to MRI findings.
Results indicate potential use of NfL as a biomarker for monitoring MS.

Implication

Investigates neurofilament light chain levels and MRI markers of progression in multiple sclerosis, suggesting a clinical role.

Abstract

To determine whether commercially obtained serum neurofilament light chain (NfL) levels were associated with MRI-based markers of multiple sclerosis (MS) progression and relapse.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hamilton et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f056663 https://doi.org/10.1212/wnl.0000000000217595

View Full Paper

Ask AI

Bookmark

Share

Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis (P6-18.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading